CELALETTİN CAMCI, SEMRA PAYDAŞ, BERKSOY ŞAHİN, BURHAN HAZAR
Annals of Medical Sciences - 2000;9(2):48-50
Purpose: To compare Ciprofloxacin and Amikacin (C+A) combination with Imipenem/Cilastatin (I/C) for empiric antibiotic therapy in febrile neutropenia patients. Methods: In this open randomised trial of 43 evaluable febrile episodes, 22 episodes were treated with C+A (Ciprofloxacin 2x500 rng p.o. and Amikacin 1x1 g i.v.) and 21 were treated with I/C (4x500 mg i.v.). In 68% of the episodes neutropenia was severe (absolute neutrophil count <500 mm3). Results: Microorganism could be isolated in 46.5% of the cases and 7% of the patients had bacteremia. The response to therapy at 72 hours and 120 hours were 27% and 52.5% in C+A group and 23% and 45.4% in I/C group respectively (for all p>0.05). Toxicity was not different in the two drug regimens but cost was more expensive in I/C group (96.5$ vs 9.1$). Conclusion: We can say that both drug regimens are equally effective in febrile neutropenia, toxicity is comparable but C+A is cheaper than I/C.
